Skip to main content
    B

    Bruker Corporation (BRKR)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $60.62
    -0.97 (-1.57%)

    Market Cap: $9.41B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Bruker Corporation (BRKR) Earnings: Report Dates and Results

    Updated Nov 4, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Bruker (BRKR) is expected to report earnings on Feb 10, 2027. In the quarter ended Sep 30, 2026, Bruker reported EPS of $0.56, above the $0.42 estimate. It beat the EPS estimate in 6 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    78%(31/40)
    Avg Surprise
    +18.58%
    Streak
    3 Q

    Upcoming Estimates

    Reports Feb 10, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$0.80
    Range$0.74 - $0.96
    14 analysts
    Revenue Consensus
    $1.03B
    Range$969.17M - $1.08B
    14 analysts
    Reports May 4, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$0.44
    Range$0.33 - $0.54
    9 analysts
    EPS Revisions
    2
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$0.44+0.6%
    60d ago$0.44+0.6%
    30d ago$0.42+3.7%
    7d ago$0.42+3.5%
    Current$0.44
    Revenue Consensus
    $856.42M
    Range$846.20M - $874.03M
    7 analysts

    Next Report

    BRKR has an expected report date of Feb 10, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 35.6% above the $0.59 reported for the quarter ended Dec 31, 2025.

    BRKR Earnings Call

    The latest BRKR earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, BRKR beat 31, missed 4 and matched 5. Revenue for the quarter ended Sep 30, 2026 was $874.00M, up 1.6% from $860.50M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$0.56$0.42$0.39 - $0.45+33.33%Beat+24.4%121 up, 1 downNov 4, 2026$874.00M
    Jun 30, 2026$0.49$0.38$0.36 - $0.40+28.95%Beat+53.1%121 up, 1 downAug 4, 2026$838.50M
    Mar 31, 2026$0.31$0.23$0.21 - $0.25+34.78%Beat-34.0%131 up, 3 downMay 6, 2026$823.40M
    Dec 31, 2025$0.59$0.65$0.62 - $0.78-9.23%Miss-22.4%141 up, 1 downFeb 12, 2026$977.20M
    Sep 30, 2025$0.45$0.32$0.30 - $0.34+40.63%Beat-25.0%122 up, 1 downNov 3, 2025$860.50M
    Jun 30, 2025$0.32$0.42$0.34 - $0.49-23.81%Miss-38.5%132 up, 3 downAug 4, 2025$797.40M
    Mar 31, 2025$0.47$0.44$0.37 - $0.50+6.82%Beat-11.3%134 up, 2 downMay 7, 2025$801.40M
    Dec 31, 2024$0.76$0.74$0.71 - $0.76+2.70%Beat+8.6%142 up, 1 downFeb 13, 2025$979.60M
    Sep 30, 2024$0.60$0.60$0.52 - $0.640.00%In line-18.9%120 up, 0 downNov 5, 2024$864.40M
    Jun 30, 2024$0.52$0.51$0.46 - $0.56+1.96%Beat+4.0%102 up, 0 downAug 6, 2024$800.70M
    Mar 31, 2024$0.53$0.46$0.45 - $0.49+15.22%Beat-17.2%100 up, 0 downMay 2, 2024$721.70M
    Dec 31, 2023$0.70$0.66$0.62 - $0.89+6.06%Beat-5.4%113 up, 0 downFeb 13, 2024$854.50M
    Sep 30, 2023$0.74$0.63$0.62 - $0.65+17.46%Beat+12.1%91 up, 0 downNov 2, 2023$742.80M
    Jun 30, 2023$0.50$0.49$0.46 - $0.50+2.04%Beat+11.1%100 up, 0 downAug 3, 2023$681.90M
    Mar 31, 2023$0.64$0.55$0.53 - $0.59+16.36%Beat+30.6%100 up, 0 downMay 4, 2023$685.30M
    Dec 31, 2022$0.74$0.72$0.69 - $0.75+2.78%Beat+25.4%104 up, 0 downFeb 9, 2023$708.40M
    Sep 30, 2022$0.66$0.56$0.52 - $0.71+17.86%Beat+4.8%100 up, 0 downNov 3, 2022$638.90M
    Jun 30, 2022$0.45$0.45$0.44 - $0.460.00%In line+2.3%90 up, 0 downAug 3, 2022$588.40M
    Mar 31, 2022$0.49$0.42$0.39 - $0.44+16.67%Beat+11.4%101 up, 0 downMay 4, 2022$595.00M
    Dec 31, 2021$0.59$0.58$0.57 - $0.61+1.72%Beat+1.7%112 up, 0 downFeb 11, 2022$683.50M
    Sep 30, 2021$0.63$0.44$0.38 - $0.48+43.18%Beat+50.0%11N/ANov 1, 2021$608.90M
    Jun 30, 2021$0.44$0.38$0.27 - $0.44+15.79%Beat+109.5%12N/AAug 2, 2021$570.80M
    Mar 31, 2021$0.44$0.33$0.29 - $0.38+33.33%Beat+214.3%12N/AMay 5, 2021$554.70M
    Dec 31, 2020$0.58$0.56$0.47 - $0.66+3.57%Beat+9.4%14N/AFeb 16, 2021$627.50M
    Sep 30, 2020$0.42$0.31$0.23 - $0.37+35.48%Beat-2.3%13N/ANov 2, 2020$511.40M
    Jun 30, 2020$0.21$0.05$0.00 - $0.17+320.00%Beat-36.4%12N/AAug 3, 2020$424.60M
    Mar 31, 2020$0.14$0.22$0.10 - $0.30-36.36%Miss-50.0%13N/AMay 6, 2020$424.00M
    Dec 31, 2019$0.53$0.59$0.56 - $0.62-10.17%Miss-1.9%14N/AMar 27, 2020$1.66B
    Sep 30, 2019$0.43$0.38$0.35 - $0.42+13.16%Beat+16.2%11N/AOct 31, 2019$1.04B
    Jun 30, 2019$0.33$0.30$0.27 - $0.36+10.00%Beat+32.0%13N/AAug 1, 2019$980.40M
    Mar 31, 2019$0.28$0.24$0.23 - $0.28+16.67%Beat+16.7%12N/AMay 2, 2019$461.40M
    Dec 31, 2018$0.54$0.54$0.51 - $0.590.00%In line+5.9%13N/AFeb 11, 2019$553.60M
    Sep 30, 2018$0.37$0.30$0.28 - $0.31+23.33%Beat+27.6%13N/ANov 1, 2018$466.60M
    Jun 30, 2018$0.25$0.25$0.18 - $0.290.00%In line+8.7%14N/AAug 2, 2018$443.70M
    Mar 31, 2018$0.24$0.23$0.19 - $0.24+4.35%Beat+26.3%14N/AMay 3, 2018$431.70M
    Dec 31, 2017$0.51$0.49$0.47 - $0.50+4.08%Beat+10.9%13N/AFeb 8, 2018$530.50M
    Sep 30, 2017$0.29$0.26$0.23 - $0.30+11.54%Beat-9.4%12N/ANov 2, 2017$435.60M
    Jun 30, 2017$0.23$0.20$0.17 - $0.26+15.00%Beat+15.0%13N/AAug 3, 2017$414.90M
    Mar 31, 2017$0.19$0.19N/A0.00%In line-9.5%N/AN/AMay 3, 2017$384.90M
    Dec 31, 2016$0.46$0.36N/A+27.78%Beat+21.1%N/AN/AFeb 13, 2017$470.30M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $1.83, down 24.1% from the year before. It was $1.19 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$1.83-24.1%
    Dec 31, 2024$2.41-6.6%
    Dec 31, 2023$2.58+10.3%
    Dec 31, 2022$2.34+11.4%
    Dec 31, 2021$2.10+55.6%
    Dec 31, 2020$1.35-14.0%
    Dec 31, 2019$1.57+12.1%
    Dec 31, 2018$1.40+14.8%
    Dec 31, 2017$1.22N/A
    Dec 31, 2016$1.19N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 8,300 words across 14 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20268,25914
    2026Q2Jun 30, 20267,19513
    2026Q1Mar 31, 20266,48012
    2025Q4Dec 31, 20257,51512
    2025Q3Sep 30, 20253,74312
    2025Q2Jun 30, 20257,32914
    2025Q1Mar 31, 20255,9379
    2024Q4Dec 31, 20247,16014

    2026Q3 Earnings Call

    Opening remarks

    Joe Kostka Director of Investor Relations Good morning. I would like to welcome everyone to Bruker Corporation's Third Quarter 2026 Earnings Conference Call. My name is Joe Kostka, and I am the Director of Bruker Investor Relations. Joining me on today's call are our President and CEO, Frank Laukien, and our EVP and CFO, Gerald Herman. In addition to the earnings release we issued earlier today, during today's conference call, we will be referencing a slide presentation that can be downloaded from the Events and Presentations section of Bruker's Investor Relations website. During today's call, we will be highlighting non-GAAP financial information. Reconciliations of our non-GAAP to GAAP financial measures are included in our earnings release and are posted on our website at ir.bruker.com. Before we begin, I would like to reference Bruker's safe harbor statement, which is shown on slide two of the presentation. During this conference call, we will or may make forward-looking statements regarding future events and the financial and operational performance of the company that involve risks and uncertainties, including those related to our recent acquisitions, geopolitical risks, wars or blockades, market demand, tariffs, currency exchange rates, competitive dynamics, or supply chains. The company's actual results may differ materially from such statements. Factors that might cause such differences include, but are not limited to, those discussed in today's earnings release and in our Form 10-K for the period ending December 31, 2025, as updated by our other SEC filings, which are available on our website and on the SEC's website. Also, please note that the following information is based on current business conditions and on our outlook as of today, November 4, 2026. We do not intend to update our forward-looking statements based on new information, future events, or for other reasons, except as may be required by law prior to the release of our fourth quarter and full year 2026 financial results, expected in February 2027. You should not rely on these forward-looking statements as necessarily representing our views or outlook as of any date after today. We will begin today's call with Frank Laukien providing an overview of our business progress. Gerald Herman will then cover the financials for the third quarter of 2026 in more detail and comment on our full year 2026 financial outlook. Now, I'd like to turn the call over to Bruker CEO, Frank Laukien.

    Frank Laukien President and CEO Thank you, Joe Kostka. Good morning, everyone, and thank you for joining us on today's third quarter 2026 earnings call. Bruker continues to drive significant advances in post-genomic disease biology solutions and drug discovery, from proteoforms to glycobiology, and from functional protein interactions to spatial biology.

    Frequently Asked Questions About BRKR

    When is Bruker's next earnings date?

    Bruker's next earnings report is expected for Feb 10, 2027.

    Did BRKR beat earnings estimates last quarter?

    Yes. Bruker reported EPS of $0.56 for the quarter ended Sep 30, 2026, above the $0.42 estimate, a 33.33% surprise.

    What EPS do analysts expect from BRKR next quarter?

    The consensus EPS estimate for Bruker for the quarter ending Dec 31, 2026 is $0.80 from 14 analysts, with estimates from $0.74 to $0.96.

    How often does BRKR beat earnings estimates?

    Bruker beat the EPS estimate in 6 of the last 8 quarters, with an average surprise of +14.27%.